Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.

Bruno CJ, Jacobson JM.

J Antimicrob Chemother. 2010 Sep;65(9):1839-41. doi: 10.1093/jac/dkq261. Epub 2010 Jul 17.

PMID:
20639524
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.

Dimitrov A.

Curr Opin Investig Drugs. 2007 Aug;8(8):653-61. Review.

PMID:
17668367
4.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
5.

Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.

Vermeire K, Schols D.

Expert Opin Investig Drugs. 2005 Oct;14(10):1199-212. Review.

PMID:
16185162
6.

Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.

Klibanov OM.

Curr Opin Investig Drugs. 2009 Aug;10(8):845-59. Review.

PMID:
19649929
7.

HIV-1 entry and entry inhibitors as therapeutic agents.

Starr-Spires LD, Collman RG.

Clin Lab Med. 2002 Sep;22(3):681-701. Review.

PMID:
12244592
8.

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR, Raffi F.

Antivir Ther. 2005;10(1):13-28. Review.

PMID:
15751760
9.

[Deep lung--cellular reaction to HIV].

Tavares Marques MA, Alves V, Duque V, Botelho MF.

Rev Port Pneumol. 2007 Mar-Apr;13(2):175-212. Review. Portuguese.

PMID:
17492233
10.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
11.
12.

HIV-1 cell entry and advances in viral entry inhibitor therapy.

Cooley LA, Lewin SR.

J Clin Virol. 2003 Feb;26(2):121-32. Review.

PMID:
12600644
13.

Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.

Vermeire K, Schols D.

J Antimicrob Chemother. 2005 Aug;56(2):270-2. Epub 2005 Jun 24. Review.

PMID:
15980096
14.

Multi-targeting the entrance door to block HIV-1.

Borkow G, Lapidot A.

Curr Drug Targets Infect Disord. 2005 Mar;5(1):3-15. Review.

PMID:
15777194
15.
16.
17.

Virus entry as a target for anti-HIV intervention.

Esté JA.

Curr Med Chem. 2003 Sep;10(17):1617-32. Review.

PMID:
12871111
18.

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

Cahn P.

Expert Opin Investig Drugs. 2004 Jan;13(1):55-68. Review.

PMID:
14680453
20.

Targeting HIV: old and new players.

Pani A, Loi AG, Mura M, Marceddu T, La Colla P, Marongiu ME.

Curr Drug Targets Infect Disord. 2002 Mar;2(1):17-32. Review.

PMID:
12462150

Supplemental Content

Support Center